Alendronate Sodium
Product Images NDC 53217-321

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 53217-321). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Arrow (Alendronate Sodium Usp 35mg Tablet 1)

Arrow (Alendronate Sodium Usp 35mg Tablet 1)
FDA Label Image

Arrow (Alendronate Sodium Usp 35mg Tablet 10)

Arrow (Alendronate Sodium Usp 35mg Tablet 10)
FDA Label Image

Alendronate Sodium, Usp Tablet (Alendronate Sodium Usp 35mg Tablet 11)

Alendronate Sodium, Usp Tablet (Alendronate Sodium Usp 35mg Tablet 11)
FDA Label Image

Arrow (Alendronate Sodium Usp 35mg Tablet 2)

Arrow (Alendronate Sodium Usp 35mg Tablet 2)
FDA Label Image

Structural Formula For Alendronate Sodium (Alendronate Sodium Usp 35mg Tablet 3)

Structural Formula For Alendronate Sodium (Alendronate Sodium Usp 35mg Tablet 3)
FDA Label Image

Cumulative Incidence Of Hip Fractures In The Three-year Study Of Fit (patients With Radiographic Vertebral Fracture At Baseline) (Alendronate Sodium Usp 35mg Tablet 4)

Cumulative Incidence Of Hip Fractures In The Three-year Study Of Fit (patients With Radiographic Vertebral Fracture At Baseline) (Alendronate Sodium Usp 35mg Tablet 4)
FDA Label Image

Osteoporosis Treatment Studies In Postmenopausal Women Increase In Bmd Alendronate Sodium 10 mg/day At Three Years (Alendronate Sodium Usp 35mg Tablet 5)

Osteoporosis Treatment Studies In Postmenopausal Women Increase In Bmd Alendronate Sodium 10 mg/day At Three Years (Alendronate Sodium Usp 35mg Tablet 5)
FDA Label Image

Osteoporosis Treatment Studies In Postmenopausal Women Time Course Of Effect Of Alendronate Sodium 10 mg/day Versus Placebo: Lumbar Spine Bmd Percent Change From Baseline (Alendronate Sodium Usp 35mg Tablet 6)

Osteoporosis Treatment Studies In Postmenopausal Women Time Course Of Effect Of Alendronate Sodium 10 mg/day Versus Placebo: Lumbar Spine Bmd Percent Change From Baseline (Alendronate Sodium Usp 35mg Tablet 6)
FDA Label Image

Osteoporosis Prevention Studies In Postmenopausal Women (Alendronate Sodium Usp 35mg Tablet 7)

Osteoporosis Prevention Studies In Postmenopausal Women (Alendronate Sodium Usp 35mg Tablet 7)
FDA Label Image

Studies In Glucocorticoid (Treated Patients Increase in BMD Alendronate Sodium 5 mg/day at One Year)

Studies In Glucocorticoid (Treated Patients Increase in BMD Alendronate Sodium 5 mg/day at One Year)
FDA Label Image

Studies In Paget’s Disease Of Bone Effect On Serum Alkaline Phosphatase Of Alendronate Sodium 40 mg/day Versus Placebo Or Etidronate 400 mg/day (Alendronate Sodium Usp 35mg Tablet 9)

Studies In Paget’s Disease Of Bone Effect On Serum Alkaline Phosphatase Of Alendronate Sodium 40 mg/day Versus Placebo Or Etidronate 400 mg/day (Alendronate Sodium Usp 35mg Tablet 9)